Skip to content

EBITDA at other companies

Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-$22.09M-23.0%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$14.65M-8.9%
Savara logo
SavaraSVRA
-$38.97M-37.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.51M-26.0%
Amgen logo
AmgenAMGN
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
Enterprise value$250.5M-51.4%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%
Debt / equity0.0×
Current ratio23.1×-24.3×

Where this comes from

Calculated from Upstream Bio, Inc.’s reported figures.

$43.6Mebit+
$49.0KDepreciation Depletion & Amortization
=-$43.57M

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s EBITDA?
Upstream Bio, Inc. (UPB) reported EBITDA of -$43.57M in Q1 2026.
How has Upstream Bio, Inc.'s EBITDA changed year-over-year?
Upstream Bio, Inc.'s EBITDA decreased by 36.3% year-over-year, from -$31.97M to -$43.57M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.